Introduction
The International Agency for Research on Cancer (IARC) initiated in 1969 a programme to evaluate carcinogenic risks to humans and to produce monographs on individual chemicals, groups of chemicals, complex mixtures, occupational exposures and, more recently, cultural habits (1-28). The evaluations of the IARC Monographs represent a hazard identification step and as such provide elements for control of carcinogens. They do not address carcinogenic potency, size of potential human risk or mechanism of action. The Monographs summarize the strength of evidence for carcinogenicity and provide information on carcinogenic hazards. For the evaluation, evidence of carcinogenicity in humans and in experimental animals, as well as other relevant data in experimental systems and in humans, are taken into account. However, in the final overall evaluation, an agent is judged to be causally associated with cancer in humans only when there is sufficient evidence derived from relevant, valid epidemiological studies. Data on carcinogenicity from studies in experimental animals and in vitro experimental systems are given less weight, because of well-known problems related with extrapolation between species. The IARC recommends, however, that in the absence of adequate human data it is biologically plausible and prudent to regard agents for which there is sufficient evidence of carcinogenicity in experimental animals as if they presented a carcinogenic risk to humans (29). The IARC thus attempts to reconcile a scientifically objective analysis of the data with an interpretation of evidence of carcinogenicity provided by experimental data that is biologically plausible, is public health orientated, and takes into account the principles of primary prevention.
In this review, based on the results of the IARC Monographs programme, we have analysed the available data on carcinogenicity in both humans and animals for various pharmaceutical agents that have had or still have medical applications (1 -28). Whenever available, data on target organs in humans and experimental animals have been compared to identify any similarities, and thus to substantiate the validity of chronic tests for carcinogenicity. The routes of administration and corresponding target organs were identified from the original papers and from the summaries of published data as reported in the Monographs.
Selection and evaluation of Pharmaceuticals
Several medicinal drugs, especially those used in cancer chemotherapy, have been shown to increase the incidence of cancer. Alkylating anticancer drugs appear primarily to be leukaemogens (30,31), though some studies suggest that they can induce tumors at other sites as well (32 -34). Moreover, experimental studies suggest that many drugs have carcinogenic properties, despite the fact that it is not always feasible to obtain relevant human data owing to the small number of exposed individuals and other methodological drawbacks. When available, however, human and animal data are in good agreement (35) .
Pharmaceuticals that are apparently associated with possible risks of carcinogenicity were selected for evaluation by the IARC as early as 1973. Four volumes of monographs deal exclusively with medicinal drugs (10,18,19,26) and a supplement contains re-evaluations of all such compounds covered in volumes 1 -42
(1).
Pharmaceutical preparations were considered in the same way as other chemicals and were assigned similarly to five groups: group 1-carcinogenic to humans; group 2A-probably carcinogenic to humans; group 2B-possibly carcinogenic to humans; group 3-not classifiable as to carcinogenicity to humans; group 4-probably not carcinogenic to humans. A substance is assigned to one of the above groups on the basis of a scientific judgement that reflects the strength of the evidence derived from studies in humans and experimental animals. In general, data are estimated as providing sufficient (S), limited (L) or inadequate (I) evidence for carcinogenicity, or evidence suggesting lack of carcinogenicity (ESLQ derived from adequate epidemiological and experimental studies. The overall evaluation is based upon all available evidence, according to the well-defined criteria applied in the IARC Monographs programme (29).
Almost 200 evaluations have been published that concern single medicinal drugs; to a much lesser extent, combined formulations, groups of therapeutic substances and additives to apothecary products were examined collectively (26). Some of these products are no longer used; others have never been used in clinical practice, sometimes because they were found to be carcinogenic during early stages of their development (phase I), and these are referred to here as 'experimental agents'. It is worth noting, however, that several Pharmaceuticals that have carcinogenic properties are still in use.
Pharmaceutical agents causally associated with cancer in humans (group 1) Of the 182 entries in Table I, 20 agents are classified as  carcinogenic to humans (12 single drugs, five combinations and  three groups or mixtures of chemicals) .
Eight of the 12 single drugs are cytostatic agents [chlornaphazine, myleran, chlorambucil, l-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea (methyl-CCNU), cyclophosphamide, melphalan, thiotepa, treosulfan], two are immunosuppressants (azathioprine and cyclosporine), one is a non-steroidal oestrogen (diethylstilboestrol), and one is a dermatological antiseptic (arsenic trioxide).
The combinations evaluated comprise analgesic formulations containing phenacetin, antineoplastic therapy with MOPP (nitrogen mustard, vincristine, procarbazine and prednisone), oral contraceptives containing oestrogens and progestins as sequential or combined formulations, and the synergistic application of 8-methoxypsoralen with ultraviolet radiation A.
Two groups of substances have been evaluated as carcinogenic, without specific reference to a single agent; these are steroidal and non-steroidal oestrogens, mainly when used as replacement therapy in postmenopausal women. Finally, the complex mixture of chemicals, coal-tars, that are applied locally to the skin for the treatment of some dermatological ailments are also carcinogenic.
Pharmaceutical agents probably or possibly carcinogenic to humans (groups 2A and 2B) Category 2A contains 14 drugs that are considered to be carcinogenic to humans with a high degree of probability (Table I) . Most have been used or tested as antineoplastic agents [adriamycin, azacitidine, bischloroethyl nitrosourea (BCNU), l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU), chlorozotccin, cisplatin, nitrogen mustard, JV-nitroscHV-methylurea and procarbazine]. The others are the analgesic phenacetin, the antibacterial chloramphenicol, the anabolic steroids oxymetholone and testosterone, and 5-methoxypsoralen, which has been used for the treatment of psoriasis and is still used relatively often in cosmetic suntan preparations (36).
Category 2B contains many agents for which there is a somewhat lower degree of probability for carcinogenicity to humans. A total of 34 single chemicals, one combined formulation (containing many agents together with the obsolete bactericidal dihydroxymethylfuratrizine) and one collective group of drugs (progestins) have been evaluated as possible carcinogens.
The single chemicals include many antineoplastic drugs (azaserine, bleomycins, dacarbazine, daunomycin, merphalan, mitomycin C, nitrogen mustard N-oxide, streptozotocin, trichlormethine and uracil mustard), the sweetener saccharin, the anaesthetic chloroform, the analgesic phenazopyridine, the antibacterials nifuradene and furothiazole, the antifungal griseofulvin, the antiseptic /3-propiolactone, the antiprotozoans metronidazole and niridazole, the antiparasitics DDT and lindane, the dermatological agent safrole, the antianaemics iron-dextran complex and cobalt chloride, the a-blocker phenoxybenzamine, the central nervous system depressants phenobarbital and phenytoin, the antithyroid agents methylthiouracil, propylthiouracil and thiourea, the progestin medroxyprogesterone, the laxative dantron, the alkaloid monocrotaline (from traditional herbal decoctions of Crotalaria sp.), a thiadiazole derivative used in gastritis, and finally two experimental agents (lasiocarpine and nafenopin).
Organ specificity of cancer in humans and animals All 77 pharmaceutical agents that have been found to be conclusively, probably or possibly carcinogenic to humans are listed in Table II , with the target organs involved.
For the vast majority of these agents, there is experimental evidence for carcinogenicity in one or more species of animals but without corresponding epidemiological data (52/77) . In only a few instances (7/77) have the results of epidemiological findings not been confirmed by experimental studies. Data on carcinogenicity derived from studies on both humans and experimental animals are available for 18 of these pharmaceutical agents (Tables I and II) .
Comparison of epidemiological and experimental data reveals a 72 % concordance of the target organs for at least one species of experimental animals. Thus, for 12 of 18 pharmaceutical agents, the organs were comparable. For the 14 pharmaceutical agents for which there is sufficient evidence for carcinogenicity to humans (group 1), there is 71 % (10/14) concordance on target organ. For the seven medicinal drugs for which there is sufficient evidence for carcinogenicity in both humans and animals (chlorambucil, cyclophosphamide, diethylstilboestrol, melphalan, thiotepa, coal-tars and 8-methoxypsoralen plus UV radiation) (Table I ), the concordance of target organs rises to 85% (6/7) ( Table II) .
Information on the human organs affected by cancer exists for 25 pharmaceutical agents, 20 of which are conclusively carcinogenic and for five of which there is limited or inadequate epidemiological evidence. The organs involved and the incriminated drugs are shown in Table HI .
With regard to route of administration, in 66% (8/12) of experiments in animals that showed similar organ specificity to that of humans, the pharmaceutical agent was administered in a way resembling that used in clinical practice. The same percentage (4/6) was found when dissimilar target organs in animals and humans were compared.
Discussion and Conclusions
Many pharmaceutical agents have been evaluated for their suspected carcinogenic properties by working groups convened by the I ARC. A considerable number could not be classified as to their carcinogenicity to humans. Of those that could be classified, some are now obsolete and others were never used because of high toxicity. Many of these drugs, however, are still widely used, and some are included in the list of Essential Drugs drawn up by WHO as absolutely necessary for basic medical treatment (287) .
A total of 36 essential drugs have been evaluated at the IARC as suspected carcinogens: 18 could not be classified as to their carcinogenicity to humans. Of the other 18, four are conclusively carcinogenic to humans (azathioprine, cyclophosphamide, combined oral contraceptives, coal-tars), five are probably carcinogenic (adriamycin, chloramphenicol, cisplatin, procarbazine, testosterone) and nine are possibly carcinogenic (bleomycin, dacarbazine, griseofulvin, iron-dextran, lindane, metronidazole, phenobarbital, phenytoin, propylthiouracil).
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antineoplastic drugs, comparisons of carcinogenic potency between humans and animals have, however, given comparable results (35). The target organs affected by carcinogenic drugs are similar to those of other environmental chemicals (288) , with the outstanding exception of the lung. This must be attributed to the fact that occupational exposure primarily affects the respiratory system. The contribution of drugs to the burden of cancer in the general population mainly concerns organs that are the targets of relatively uncommon cancers (289) .
An important consideration with respect to drugs, especially those that are not strongly associated with the production of neoplasms, is the risk-benefit ratio. In the developing world, where many fatal diseases are endemic, the short-term usefulness of a drug may be considered to outweigh by far the possible or probable risk of cancer. The same view prevails in modern clinical medicine with respect to the antineoplastic and immunosuppressive drugs, which are highly toxic and very often carcinogenic. The indications for using such drugs should be fully justified on ethical groups.
Some pharmaceuticals, although not classifiable as to their carcinogenicity to humans, have been incriminated in experimental studies and may therefore represent serious public health problems. Substances for which there is sufficient or even limited experimental evidence of carcinogenicity should not be used in over-the-counter preparations, in which overconsumption may occur. 
